CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
Curis, Inc.
Amgen
Kousai Bio Co., Ltd.
Thomas Jefferson University
The First Affiliated Hospital of Soochow University
Yale University
Genmab
St. Jude Children's Research Hospital
Beijing Biotech
Memorial Sloan Kettering Cancer Center
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Memorial Sloan Kettering Cancer Center
Hangzhou Sumgen Biotech Co., Ltd.
Bristol-Myers Squibb
The First Affiliated Hospital of Soochow University
Medical College of Wisconsin
Novartis
Daiichi Sankyo
H. Lee Moffitt Cancer Center and Research Institute
Keystone Nano, Inc
Servier
AbbVie
AstraZeneca
Sumitomo Pharma America, Inc.
Tcelltech Inc.
Curis, Inc.
Cellectar Biosciences, Inc.
Vanda Pharmaceuticals
Radboud University Medical Center
Sellas Life Sciences Group
University of Illinois at Chicago
Dana-Farber Cancer Institute
Gilead Sciences
Memorial Sloan Kettering Cancer Center
Allogene Therapeutics
Auron Therapeutics, Inc.
Autolus Limited
M.D. Anderson Cancer Center
University of Rochester
Ascentage Pharma Group Inc.
Children's Hospital Medical Center, Cincinnati
Senti Biosciences
Dana-Farber Cancer Institute
SymBio Pharmaceuticals
BIOHENG THERAPEUTICS US LLC
Incyte Corporation
Baylor College of Medicine
NextCure, Inc.
Prelude Therapeutics
Federal Research Institute of Pediatric Hematology, Oncology and Immunology